Pradhan, Aruna D.

C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus

Pradhan, A. D. (2001) · JAMA

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 4,433

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet

Inflammasome and immune disordersInflammatory Biomarkers in Disease Prognosis

Cited by 1,344

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine

Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular Health

Cited by 1,317

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 816

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal

Atherosclerosis and Cardiovascular DiseasesInflammatory Biomarkers in Disease Prognosis

Cited by 368

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 319

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Pradhan, A. D., Aday, A. W., Rose, L. M., & Ridker, P. M. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 258

Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women

Pradhan, A. D., Rifai, N., Buring, J. E., & Ridker, P. M. (2007) · The American Journal of Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 189

Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association

Creager, M. A., Matsushita, K., Arya, S., Beckman, J. A., Duval, S., Goodney, P. P., Gutierrez, J. A. T., Kaufman, J. A., Joynt Maddox, K. E., Pollak, A. W., et al. (2021) · Circulation

Peripheral Artery Disease ManagementDiabetic Foot Ulcer Assessment and Management

Cited by 164

Obesity, Metabolic Syndrome, and Type 2 Diabetes: Inflammatory Basis of Glucose Metabolic Disorders

Pradhan, A. (2007) · Nutrition Reviews

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 145

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial

Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 117

Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Data from the Women's Health Study

Lee, T. C., Glynn, R. J., Peña, J. M., Paynter, N. P., Conen, D., Ridker, P. M., Pradhan, A. D., Buring, J. E., & Albert, M. A. (2011) · PLoS ONE

Health disparities and outcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 116

Type 2 diabetes mellitus and risk of incident atrial fibrillation in women

Schoen, T., Pradhan, A. D., Albert, C. M., & Conen, D. (2012) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 106

Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication

Pandey, A., Banerjee, S., Ngo, C., Mody, P., Marso, S. P., Brilakis, E. S., Armstrong, E. J., Giri, J., Bonaca, M. P., Pradhan, A., et al. (2017) · JACC: Cardiovascular Interventions

Peripheral Artery Disease ManagementCardiovascular and exercise physiology

Cited by 89

Association of the Mediterranean Diet With Onset of Diabetes in the Women’s Health Study

Ahmad, S., Demler, O. V., Sun, Q., Moorthy, M. V., Li, C., Lee, I.-M., Ridker, P. M., Manson, J. E., Hu, F. B., Fall, T., et al. (2020) · JAMA Network Open

Nutritional Studies and DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 54

Expanding the triglyceride range in clinical trials: therapeutic opportunities

Nordestgaard, A. T., Pradhan, A. D., Everett, B. M., MacFadyen, J. G., Bhatt, D. L., Visseren, F. L. J., Libby, P., Santos, R. D., Nissen, S. E., Nordestgaard, B. G., et al. (2025) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 20